Salvage therapy of reactive capillary hemangiomas: Apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer

• Published in: Journal of cancer research and therapeutics Vol. 15; no. 7; pp. 1624 - 1628
• Main Authors: Li, Wenhong, Wei, Zhigang, Yang, Xia, Huang, Guanghui, Han, Xiaoying, Ni, Yang, Wang, Jiao, Meng, Min, Zou, Zhigeng, Wen, Qiang, Ye, Xin
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.01.2019; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd
• Subjects: Activities of daily living; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Biopsy; Cancer therapies; Carcinoma, Non-Small-Cell Lung - complications; Carcinoma, Non-Small-Cell Lung - drug therapy; Care and treatment; Cell death; Female; Health aspects; Hemangioma, Capillary - diagnosis; Hemangioma, Capillary - etiology; Hemangioma, Capillary - therapy; Humans; Immunohistochemistry; Incidence; Inhibitor drugs; Intervention; Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - complications; Lung Neoplasms - drug therapy; Male; Middle Aged; Monoclonal antibodies; Patient outcomes; Patients; Pneumonia; Pyridines - therapeutic use; Salvage Therapy; Skin; Targeted cancer therapy; Treatment Outcome; Tumors; China; Apatinib; non-small cell lung cancer; reactive capillary hemangiomas; camrelizumab
• ISSN: 0973-1482; 1998-4138
• DOI: 10.4103/jcrt.JCRT_997_19

Background: Camrelizumab is a promising anti-programmed cell death-1 agent for non-small cell lung cancer (NSCLC) and induces reactive capillary hemangiomas (RCHs). Routine clinical management of this unique and prevalent toxicity has been summarized in previous studies. The objective of this study was to provide evidence of apatinib as a salvage therapy for RCHs. Materials and Methods: In this single-center, observational study, patients with NSCLC who were over 18 years of age and treated with camrelizumab were enrolled. The incidence of RCHs, onset and duration time, severity, evolution, and clinical practices, especially with apatinib, for their management and impact on quality of life, were recorded during a 6-month follow-up. Results: A total of 28 patients were included. The incidence of RCHs was 28.6% (8/28). The median onset and duration time were 6 weeks and 8 weeks, respectively. Six (21.4%) patients had mild and moderate RCHs and four (9.3%) patients achieved a rapid regression of RCHs with the application of apatinib. The impact of the RCHs on quality of life was limited and assessed with Dermatology Life Quality Index scores. No treatment-associated termination was observed. Conclusion: The combination of camrelizumab and apatinib in the treatment of NSCLC reduced the incidence of RCHs. Apatinib appeared to be a salvage therapy of RCHs, which leads to rapid regression of RCHs with no impairment on the quality of life.